Development and Evaluation of Implanted In Situ Gel Formulation for Treatment of Osteoarthritis

The primary aim of the present study was to develop and assess a topical gel containing Diacerein-loaded transferosomes in order to address the limitations of oral administration of Diacerein in the treatment of Osteoarthritis.Osteoarthritis, the prevailing kind of arthritis, is the primary cause of disability and lacks effective symptomatic treatment options.Diacerein hinders the interaction with the function of interleukin 1-β and is beneficial in the palliative management of osteoarthritis, while it also induces diarrhoea when taken orally.Diacerein is rapidly eliminated from the body since it has a short half-life.Therefore, a sustained release formulation is necessary for long-term administration in order to enhance patient adherence.Osteoarthritis, unlike other joint disorders, specifically affects one or a few joints.This characteristic allows for targeted Intra-articular treatment, minimising the potential for systemic adverse effects.An enhanced delivery mechanism is urgently required to enhance bioavailability and mitigate drug-related toxicity and the inefficacy of anti-inflammatory medicines.An investigation was conducted to assess the efficacy of Diacerein in situ gel as a potential treatment for Osteoarthritis.The formulation consists of poloxamer 407 as the primary polymer, hydroxypropyl methylcellulose K4, and carbopol 934 as the copolymer.It is manufactured using the conventional cold technique and is distinguished by multiple properties.All characterizations yielded satisfactory outcomes.The drug release is conducted in vitro using a phosphate buffer solution with a pH of 7.4, which indicates a regulated release of the medication.